INTENSITY THERAPEUTICS, INC.(INTS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
INTS Stock Analysis & AI Quality Score
AI stock analysis and institutional research for INTENSITY THERAPEUTICS, INC. (INTS), a Healthcare sector company. INTS is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), INTENSITY THERAPEUTICS, INC. reports net income of $-2.4M, free cash flow of $-1.8M. Top institutional holders of INTS by reported 13-F value include GEODE CAPITAL MANAGEMENT,, SAPIENT CAPITAL, NANO CAP NEW MILLENNIUM GROWTH FUND L P, based on the most recent SEC filings. INTS trades on the Nasdaq exchange and files with the SEC under CIK 1567264. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INTS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for INTENSITY THERAPEUTICS, INC. directly from SEC EDGAR.
Net Income
Q1 2026
$-2.4M
Free Cash Flow
Q1 2026
$-1.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-54.4% YoYOperating Income
-99.4% YoYEPS (Diluted)
-2018.8% YoYTotal Assets
-72.3% YoYOp. Cash Flow
-111.2% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Net Income | $-16.3M -54.4% | $-10.5M -39.0% | $-7.6M | — |
| Operating Income | $-16.6M -99.4% | $-8.3M -10.2% | $-7.5M | — |
| EPS (Diluted) | $-29.24 -2018.8% | $-1.38 +37.8% | $-2.22 | — |
| Total Assets | $4.8M -72.3% | $17.3M +884.3% | $1.8M | — |
| Operating Cash Flow | $-15.2M -111.2% | $-7.2M -31.6% | $-5.5M | — |
AI Insight: INTS Financial Trends
Burn rate improved 60% from $5M quarterly loss in Q2 2024 to $2M in Q1 2026, while equity strengthened to $10M.
• Net losses decreased from $5M in Q2 2024 to $2M in Q1 2026, showing consistent burn rate improvement.
• Operating cash flow improved from $4M outflow in Q2 2024 to $2M outflow in recent quarters.
• Equity recovered from $0M in Q1 2025 to $10M in Q1 2026 following apparent capital raises.
⚠ Company remains pre-revenue with no debt financing, creating ongoing funding dependency for operations.
⚠ Equity declined from $12M in Q4 2025 to $10M in Q1 2026 despite reduced burn rate.
AI Insight: INTS Ratio Trends
INTS shows minimal financial data with sparse quarterly reporting, limiting meaningful trend analysis across most key metrics.
• ROE improved from -147.9% in Q3 2025 to -97.6% in Q1 2026, showing reduced losses relative to equity.
• ROA strengthened from -86.6% in Q4 2025 to -79.2% in Q1 2026, indicating better asset utilization.
⚠ Operating margin, net profit margin, ROIC, and debt-to-equity ratios remain unreported across all quarters.
⚠ Company continues posting negative returns with ROE of -97.6% and ROA of -79.2% in latest quarter.
Get alerted when INTS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for INTENSITY THERAPEUTICS, INC. including:
Top Institutional Holders of INTS
GEODE CAPITAL MANAGEMENT, LLC
$153.0K26,019 shSAPIENT CAPITAL LLC
$152.9K26,006 shNANO CAP NEW MILLENNIUM GROWTH FUND L P
$147.0K25,000 shSentinus, LLC
$137.0K23,294 shVANGUARD CAPITAL MANAGEMENT LLC
$99.0K16,841 shMesirow Financial Investment Management, Inc.
$83.0K14,118 shVANGUARD FIDUCIARY TRUST CO
$53.6K9,121 shOSAIC HOLDINGS, INC.
$1.2K200 shWELLS FARGO & COMPANY/MN
$1.2K200 shUBS Group AG
$1.1K192 sh
| Fund | Value | Shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | $153.0K | 26,019 |
| SAPIENT CAPITAL LLC | $152.9K | 26,006 |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | $147.0K | 25,000 |
| Sentinus, LLC | $137.0K | 23,294 |
| VANGUARD CAPITAL MANAGEMENT LLC | $99.0K | 16,841 |
| Mesirow Financial Investment Management, Inc. | $83.0K | 14,118 |
| VANGUARD FIDUCIARY TRUST CO | $53.6K | 9,121 |
| OSAIC HOLDINGS, INC. | $1.2K | 200 |
| WELLS FARGO & COMPANY/MN | $1.2K | 200 |
| UBS Group AG | $1.1K | 192 |
More Healthcare Companies
View all Healthcare →Put INTS on your watchlist
Track score changes the day INTENSITY THERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is INTS a good stock to buy?
13F Pro's AI-powered analysis of INTENSITY THERAPEUTICS, INC. (INTS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INTS are available on the INTS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own INTS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INTS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of INTENSITY THERAPEUTICS, INC.'s investment landscape.